Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
Moderna(MRNA) stock is priced at $48.99, giving the company a market capitalization of 19.34B. It carries a P/E multiple of -5.73.
On 2026-05-06, Moderna(MRNA) stock moved within a range of $46.73 to $49.05. With shares now at $48.99, the stock is trading +4.8% above its intraday low and -0.1% below the session's peak.
Trading volume for Moderna(MRNA) stock has reached 4.39M, versus its average volume of 5.69M.
Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $59.55 and a low of $22.28.
Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $59.55 and a low of $22.28.
MRNA News
Wondering whether Moderna's current share price still reflects its true value, or if the market has moved on too quickly. The stock closed at US$46.71, with a...
Moderna (MRNA) is back in focus after first quarter 2026 results, with revenue of US$389 million, a GAAP net loss of US$1.343b, new EU vaccine approvals, and pr...
The company states: “Today, Vertex (VRTX) announced that it has decided to discontinue the Phase 1/2 study of the investigational inhaled CFTR mRNA candidate fo...
Analyst ratings
65%
of 26 ratingsMore MRNA News
Moderna ((MRNA)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and powerful in...
Earnings Call Insights Moderna expects up to 10% 2026 revenue growth and $4.5B-$5B year-end cash, while targeting ~$4.2B cash costs May 01, 2026, 5:52 PM ET Mod...
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...
In April 2026, the European Commission granted marketing authorization for Moderna’s mCOMBRIAX (mRNA-1083), the first approved mRNA combination influenza and CO...
William Blair analyst Myles Minter has maintained their neutral stance on MRNA stock, giving a Hold rating on April 28. Unlock hedge fund-level data and powerf...
Moderna Revenue Beats Despite Litigation Impact The COVID-19 vaccine maker reported a first-quarter adjusted loss of $1.18 per share, narrower than analysts’ e...
Moderna (MRNA) added ~9% in the premarket on Friday after the Massachusetts-based biotech reported better-than-expected Q1 2026 financials, thanks mainly to hig...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.